HKEX
Every company in the roster listed on HKEX.
Every company in the roster listed on HKEX.
53 of 53 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
3D Medicines Inc.1244 · HKEX | 2 assets: 2 Ph 3 | EnvafolimabPhase 3 · Non-Small Cell Lung CancerWeak signal | Dec 2026Envafolimab · Phase 2 | — | $61MDec 2024 | ~9.6 qtrs | — |
Abbisko Therapeutics2256 · HKEX | 3 assets: 2 Ph 2, 1 Ph 1 | LavengratinibPhase 2 · Non-Small Cell Lung Cancer | Mar 2027ABSK112 · Phase 1 | — | $286MDec 2025 | — | $71M |
Akeso9926 · HKEX | 12 assets: 1 approved, 6 Ph 3, 5 Ph 2 | IvonescimabPhase 3 · Non-Small Cell Lung CancerReliable signal | Nov 2026Cadonilimab · Phase 3 | — | $1.0BDec 2024 | ~14.1 qtrs | $166M |
Alebund Pharmaceuticals9637 · HKEX | 1 asset: 1 Ph 3 | AP301 (fiber-iron phosphate binder)Phase 3 · Chronic Kidney DiseasePartial signal | None on record | — | — | — | $52M |
Alphamab Oncology9966 · HKEX | 4 assets: 2 Ph 3, 2 Ph 2 | Anbenitamab repodatecanPhase 3 · HR+/HER2- Metastatic Breast Cancer | 30 Dec 2026Anbenitamab repodatecan · Phase 3 | — | $193MDec 2025 | ~12.2 qtrs | ~$70M |
Antengene Corporation Limited6996 · HKEX | 2 assets: 1 approved, 1 Ph 2 | OnatasertibPhase 2 · Non-Small Cell Lung CancerWeak signal | Dec 2026Selinexor · Phase 2/3 | — | $111MJun 2025 | ~21.0 qtrs | ~$22M |
Ascletis Pharma1672 · HKEX | 4 assets: 3 Ph 3, 1 Ph 1 | DenifanstatPhase 3 · Recurrent GlioblastomaReliable signal | Dec 2026Envafolimab · Phase 2 | — | $206MDec 2025 | ~4.1 qtrs | $57M |
Beijing Biostar Pharmaceuticals2563 · HKEX | 1 asset: 1 Ph 3 | UtidelonePhase 3 · Non-Small Cell Lung CancerPartial signal | 1 Dec 2026Utidelone · Phase 2 | — | — | — | — |
Beijing InnoCare Pharma Tech Co.9969 · HKEX | 5 assets: 1 approved, 3 Ph 3, 1 Ph 2 | FadeucravacitinibPhase 3 · PsoriasisPartial signal | 25 Nov 2026Soficitinib (ICP-332) · Phase 3 | — | $1.1BMar 2026 | Profitable | ~$132M |
Brii Biosciences2137 · HKEX | 1 asset: 1 Ph 3 | Tobevibart (VIR-3434)Phase 3 · Chronic Hepatitis Delta | Dec 2026Tobevibart (VIR-3434) · Phase 3 | — | — | — | — |
CARsgen Therapeutics Holdings Limited2171 · HKEX | 2 assets: 2 Ph 2 | Zevorcabtagene autoleucelPhase 1/2 · Multiple MyelomaWeak signal | 15 Jun 2027CT071 · Phase 1/2 | — | $203MDec 2024 | Ended Oct 2026 | $66M |
China Medical System867 · HKEX | 9 assets: 5 approved, 4 Ph 3 | DesidustatPhase 3 · Chronic Kidney DiseasePartial signal | 31 Jan 2027CMS-D001 · Phase 2 | — | — | — | $81M |
Consun Pharmaceutical Group1681 · HKEX | 1 asset: 1 Ph 1 | SK-08Phase 1 · Chronic Kidney Disease | None on record | — | $176MDec 2025 | — | — |
CSPC Pharmaceutical Group1093 · HKEX | 11 assets: 8 Ph 3, 2 Ph 2, 1 other | PrusogliptinPhase 3 · Type 2 DiabetesReliable signal | 30 Dec 2026Anbenitamab repodatecan · Phase 3 | — | $1.4BDec 2025 | — | $809M |
CStone Pharmaceuticals2616 · HKEX | 2 assets: 1 approved, 1 Ph 3 | SugemalimabPhase 3 · Non-Small Cell Lung CancerReliable signal | 30 Jul 2027Pralsetinib · Approved | — | $131MDec 2025 | Ended Jul 2026 | $43M |
DualityBio Inc.9606 · HKEX | 5 assets: 2 Ph 3, 3 Ph 2 | Trastuzumab pamirtecanPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signal | Aug 2027Trastuzumab pamirtecan · Phase 1/2 | — | — | — | — |
Edding Genor Group Holdings Limited6998 · HKEX | 1 asset: 1 Ph 2 | EDP167Phase 2 · Atherosclerotic Cardiovascular DiseaseWeak signal | Nov 2027EDP167 · Phase 2 | — | — | Ended Jun 2024Dec 2023 | — |
Essex Bio-Technology Limited1061 · HKEX | 1 asset: 1 Ph 3 | HLX04-OPhase 3 · Age-Related Macular DegenerationPartial signal | None on record | — | — | — | — |
Everest Medicines (Beijing) Co., Ltd.1952 · HKEX | 7 assets: 2 approved, 4 Ph 3, 1 Ph 2 | LerodalcibepPhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | 26 Nov 2026MT1013 · Phase 3 | — | — | — | — |
GenFleet Therapeutics2595 · HKEX | 3 assets: 1 Ph 3, 2 Ph 2 | GFH375Phase 3 · Non-Small Cell Lung Cancer | 30 Apr 2027GFH375 · Phase 2 | — | — | — | $46M |
Hansoh Pharmaceutical Group3692 · HKEX | 17 assets: 1 approved, 10 Ph 3, 3 Ph 2, 3 Ph 1 | olatorepatidePhase 3 · ObesityReliable signal | 25 Dec 2026HS-20118 · Phase 1 | — | $4.5BDec 2025 | — | $468M |
Harbour BioMed2142 · HKEX | 2 assets: 1 Ph 3, 1 Ph 1 | WIN378Phase 2/3 · AsthmaWeak signal | 17 Dec 2027WIN378 · Phase 2 | — | — | — | — |
HighTide Biopharma2511 · HKEX | 1 asset: 1 Ph 3 | Berberine ursodeoxycholate (HTD1801)Phase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
Hua Medicine2552 · HKEX | 2 assets: 1 Ph 3, 1 Ph 1 | DorzagliatinPhase 3 · Type 2 DiabetesPartial signal | None on record | — | $156MDec 2025 | — | $20M |
ImmuneOnco Biopharmaceuticals1541 · HKEX | 2 assets: 2 Ph 2 | Palverafusp alfaPhase 2 · Non-Small Cell Lung Cancer | 20 May 2027IMC-003 · Phase 1 | — | — | — | ~$46M |
Innovent Biologics1801 · HKEX | 18 assets: 4 approved, 9 Ph 3, 3 Ph 2, 2 Ph 1 | IBI305Phase 3 · Non-Small Cell Lung CancerReliable signal | 30 Nov 2026IBI363 · Phase 2 | — | $2.6BDec 2025 | 10+ years | $387M |
Insilico Medicine3696 · HKEX | 1 asset: 1 Ph 2 | garutadustatPhase 2 · Ulcerative Colitis | 15 Aug 2027garutadustat · Phase 2 | — | $393MDec 2025 | ~4.5 qtrs | $81M |
Jacobio Pharmaceuticals1167 · HKEX | 4 assets: 2 Ph 3, 2 Ph 2 | GlecirasibPhase 3 · Non-Small Cell Lung CancerWeak signal | 31 Dec 2026JAB-23E73 · Phase 1/2 | — | $149MJun 2025 | ~18.4 qtrs | ~$26M |
Keymed Biosciences2162 · HKEX | 6 assets: 4 Ph 3, 1 Ph 2, 1 Ph 1 | stapokibartPhase 3 · Atopic DermatitisReliable signal | Dec 2026Gamgertamig (CM336) · Phase 1/2 | — | $280MDec 2025 | ~3.8 qtrs | $100M |
Laekna Limited2105 · HKEX | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | AfuresertibPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signal | 30 Jun 2027LAE102 · Phase 1 | — | $165MJun 2026 | 10+ years | ~$28M |
Lee's Pharmaceutical0950 · HKEX | 4 assets: 2 Ph 3, 1 Ph 2, 1 other | Loxapine (Adasuve)Phase 3 · SchizophreniaReliable signal | Dec 2028Istaroxime · Phase 2/3 | — | $45MDec 2025 | — | $14M |
Luye Pharma Group2186 · HKEX | 12 assets: 4 approved, 4 Ph 3, 2 Ph 2, 2 Ph 1 | Ansofaxine hydrochloridePhase 3 · Major Depressive DisorderReliable signal | 28 Feb 2027Ansofaxine hydrochloride · Approved | — | — | — | $260M |
Nanjing Leads Biolabs Co.,Ltd9887 · HKEX | 3 assets: 2 Ph 2, 1 Ph 1 | OpamtistomigPhase 2 · Non-Small Cell Lung Cancer | Dec 2026Opamtistomig · Phase 1/2 | — | $59MMar 2025 | Ended Sep 2026 | ~$32M |
PegBio2565 · HKEX | 3 assets: 2 Ph 3, 1 Ph 2 | Visepegenatide (PB-119)Phase 3 · Type 2 DiabetesReliable signal | None on record | — | — | — | — |
Qyuns Therapeutics2509 · HKEX | 1 asset: 1 Ph 3 | HS-20137Phase 3 · Psoriasis | 1 Mar 2027HS-20137 · Phase 2 | — | — | — | — |
Shaanxi Micot Pharmaceutical Technology2335 · HKEX | 1 asset: 1 Ph 3 | MT1013Phase 3 · Chronic Kidney DiseasePartial signal | 26 Nov 2026MT1013 · Phase 3 | — | — | — | ~$11M |
Shandong Boan Biotechnology Co., Ltd6955 · HKEX | 1 asset: 1 Ph 1 | BA1302Phase 1 · Non-Small Cell Lung Cancer | 31 Dec 2027BA1302 · Phase 1 | — | — | — | $11M |
Shanghai Bao Pharmaceuticals Co., Ltd.2659 · HKEX | 1 asset: 1 Ph 1 | KJ015Phase 1 · Non-Small Cell Lung Cancer | 31 Dec 2026KJ015 · Phase 1 | — | — | — | — |
Shanghai Henlius Biotech2696 · HKEX | 14 assets: 8 Ph 3, 4 Ph 2, 2 Ph 1 | HLX01Phase 3 · Rheumatoid ArthritisReliable signal | 22 Nov 2026HLX43 · Phase 2 | — | — | — | $347M |
Shanghai Junshi Bioscience1877 · HKEX | 8 assets: 1 approved, 4 Ph 3, 2 Ph 2, 1 Ph 1 | OngericimabPhase 3 · Atherosclerotic Cardiovascular DiseaseReliable signal | 27 Nov 2026JS207 · Phase 2 | — | $456MDec 2025 | ~3.7 qtrs | $193M |
| 7 assets: 3 Ph 3, 3 Ph 2, 1 Ph 1 | Sacituzumab TirumotecanPhase 3 · Non-Small Cell Lung CancerPartial signal | Nov 2026Sacituzumab Tirumotecan · Phase 3 | — | $651MDec 2025 | ~12.2 qtrs | $184M | |
Sihuan Pharmaceutical Holdings0460 · HKEX | 1 asset: 1 Ph 3 | janagliflozinPhase 3 · Type 2 DiabetesReliable signal | 31 Dec 2027janagliflozin · Approved | — | $509MDec 2025 | — | $41M |
Simcere Pharmaceutical2096 · HKEX | 9 assets: 7 Ph 3, 2 Ph 1 | ZemprocitinibPhase 3 · Atopic DermatitisReliable signal | Nov 2026Zemprocitinib · Phase 3 | — | — | Profitable | — |
Sino Biopharmaceutical1177 · HKEX | 16 assets: 1 approved, 7 Ph 3, 4 Ph 2, 4 Ph 1 | CulmerciclibPhase 3 · HR+/HER2- Metastatic Breast CancerPartial signal | Dec 2026Culmerciclib · Phase 3 | — | $1.8BDec 2025 | — | $866M |
SinoMab BioScience3681 · HKEX | 1 asset: 1 Ph 2 | SM17Phase 2 · Atopic DermatitisWeak signal | 25 Apr 2027SM17 · Phase 2 | — | — | — | — |
Sunho Biologics2898 · HKEX | 2 assets: 1 Ph 2, 1 Ph 1 | IAP0971Phase 1/2 · Non-Small Cell Lung Cancer | 28 Feb 2027ISH0688 · Phase 1 | — | $24MJun 2025 | Ended Aug 2026 | — |
Suzhou Ribo Life Science6938 · HKEX | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | QLC7401Phase 3 · Atherosclerotic Cardiovascular Disease | 7 Oct 2027QLC7401 · Phase 3 | — | — | — | $39M |
TransThera Sciences (Nanjing), Inc.2617 · HKEX | 1 asset: 1 Ph 3 | TinengotinibPhase 3 · CholangiocarcinomaWeak signal | Dec 2026Tinengotinib · Phase 3 | — | — | — | — |
TYK Medicines, Inc.2410 · HKEX | 1 asset: 1 Ph 3 | AsandeutertinibPhase 3 · Non-Small Cell Lung CancerWeak signal | 1 Dec 2027Asandeutertinib · Phase 2 | — | — | — | $34M |
Vigonvita Life Sciences2630 · HKEX | 2 assets: 2 Ph 2 | LV232Phase 2 · Major Depressive DisorderWeak signal | 1 Sep 2027LV232 · Phase 2 | — | — | — | — |
VISEN Pharmaceuticals2561 · HKEX | 2 assets: 2 approved | Approved assets only | Aug 2027palopegteriparatide · Phase 3 | — | — | — | — |
Wuhan YZY Biopharma Co., Ltd.2496 · HKEX | 2 assets: 1 Ph 2, 1 Ph 1 | M701Phase 1/2 · Non-Small Cell Lung Cancer | None on record | — | $14MDec 2025 | ~4.8 qtrs | — |
Xuanzhu Biopharmaceutical2575 · HKEX | 4 assets: 2 Ph 3, 1 Ph 2, 1 Ph 1 | BireociclibPhase 3 · HR+/HER2- Metastatic Breast CancerReliable signal | None on record | — | — | — | $26M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.